Clinical Trial Update: Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating the effect of erugliflozin on liver fat, liver fibrosis, and glycemic control in patients with type 2 diabetes and NASH/NAF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Erugliflozin (Erugliflozin)

Snippet

Sponsor: Getz Pharma | Conditions: Liver Fat, Liver Fibrosis | Phase 4 | Status: RECRUITING